The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
Weinstein
H
H
Ravindranath
Y
Y
Krischer
J
J
Steuber
P
P
Civin
C
C
Gresik
M
M
Vietti
T
T
D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin